Onco-Summaries: Daily Oncology Updates at a Glance
02/09/2026
Ivonescimab demonstrated OS benefit vs pembrolizumab in PD‑L1+ NSCLC (Ref)
Summit Therapeutics announced that in a Phase 3 HARMONi-2 China study, ivonescimab monotherapy demonstrated a statistically significant overall survival (OS) benefit vs pembrolizumab in PD-L1–positive advanced NSCLC patients
Ivonescimab previously showed a strong progression-free survival (PFS) benefit (HR 0.51; p<0.0001)
A clinically meaningful benefit was demonstrated across clinical subgroups, including those with PD-L1 low expression, PD-L1 high expression, squamous, and non-squamous histologies
Detailed results from the trial are scheduled to be presented at an upcoming medical conference
China’s NMPA granted marketing authorization for ivonescimab in April 2025 based on the results of HARMONi-2
Comments